All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, Which relapsed/refractory AML subgroups would benefit from enasidenib treatment?
Which R/R AML subgroups would benefit from enasidenib treatment?
DiNardo begins by explaining the importance of an IDH2 mutation for the efficacy of this targeted inhibitor. She then reports on promising results from the enasidenib versus conventional care regimens trial.
Editorial theme | Novel combination therapies using targeted agents
This article provides a summary of content relating to novel agent-containing combinations to date & introduces the new editorial theme of ‘Novel combination therapies using...
1st NCRI AML academy meeting | What is the optimum treatment strategy for elderly or frail patients with AML?
Prof Courtney DiNardo spoke to us at the 1st NCRI AML academy meeting on the topic of the optimum strategy for the treatment of elderly or...
Subscribe to get the best content related to AML delivered to your inbox